Tafolecimab clinical trials
Also written IBI306.
How each study uses tafolecimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the tafolecimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
17 studies that test it; most in 2019 (4); 1 more planned to start later
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 4 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 10
Innovent Biologics (Suzhou) Co. Ltd. (8) · Beijing Tiantan Hospital (1) · Guangdong Provincial People's Hospital (1) · First Affiliated Hospital of Zhejiang University (1) · The Affiliated Hospital of Xuzhou Medical University (1) · Anhui Provincial Cancer Hospital (1) · China National Center for Cardiovascular Diseases (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1)
Often tested with
Tested in the same studies.
Sintilimab (4) · Sitagliptin (1) · Zeprumetostat (1) · Ursodeoxycholic Acid (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 6
Studies that test tafolecimab.
- Dec 2026INtensive liPid-lowering Therapy for Acute High-risk IntracRanial or Extracranial atheroSclerosis -II (INSPIRES-2)Not applicable · Beijing Tiantan Hospital
- May 2027PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1/L1 TherapyPhase 2 · Anhui Provincial Cancer Hospital
- May 2027A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.Phase 2 · Jinghui Wang
- Aug 2027Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung CancerPhase 2 · Second Affiliated Hospital, Zhejiang University, School of Medicine
- Sep 2027Tafolecimab Combined With Sintilimab and SOX in the Treatment of pMMR/MSS Gastric CancerPhase 2 · First Affiliated Hospital of Zhejiang University
- Nov 2027Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary Intervention on Acute Myocardial Infarction PatientsPhase 4 · The Affiliated Hospital of Xuzhou Medical University
Studies
Open first, then newest update. How each study uses tafolecimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 18
- Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese PopulationRecruitingPhase 4China National Center for Cardiovascular DiseasesNCT06096909Written as Tafolecimab
- INtensive liPid-lowering Therapy for Acute High-risk IntracRanial or Extracranial atheroSclerosis -II (INSPIRES-2)Not yet recruitingNot applicableBeijing Tiantan HospitalNCT07341958Written as Tafolecimab
- Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung CancerRecruitingPhase 2Second Affiliated Hospital, Zhejiang University, School of MedicineNCT07061535Written as Tafolecimab
- Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder CancerRecruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07717242Written as Tafolecimab
- Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled TrialNot yet recruitingPhase 3Guangdong Provincial People's HospitalNCT07686796Written as Tafolecimab
- Tafolecimab Combined With Sintilimab and SOX in the Treatment of pMMR/MSS Gastric CancerNot yet recruitingPhase 2First Affiliated Hospital of Zhejiang UniversityNCT07621562Written as Tafolecimab plus Sintilimab combined with SOX
- Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary Intervention on Acute Myocardial Infarction PatientsNot yet recruitingPhase 4The Affiliated Hospital of Xuzhou Medical UniversityNCT06683131Written as Tafolecimab
- PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1/L1 TherapyNot yet recruitingPhase 2Anhui Provincial Cancer HospitalNCT07014215Written as Sintilimab combined with Bevacizumab and tafolecimab
- A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.RecruitingPhase 2Jinghui WangNCT06421298Written as Tafolecimab
- IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed HyperlipidemiaActive, not recruitingPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT07473960Written as IBI306
- A Study of IBI306 in Participants With HypercholesterolemiaCompletedPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT04709536Written as IBI306
- Multiple Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Chinese Patients With HypercholesterolemiaCompletedPhase 2Innovent Biologics (Suzhou) Co. Ltd.NCT03815812Written as IBI306
- Bioequivalence Study of Tafolecimab Injections in Chinese Healthy Male VolunteersCompletedPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT05792917Written as tafolecimab (a modified manufacturing process)
- Safety and Efficacy of IBI306 in HeFH PatientsCompletedPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT04179669Written as IBI306
- A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial HypercholesterolemiaCompletedPhase 2/3Innovent Biologics (Suzhou) Co. Ltd.NCT04031742Written as IBI306
- Safety and Efficacy of IBI306 in Chinese Subjects With Non-familial HypercholesterolemiaCompletedPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT04289285Written as IBI306 450mg SC Q4W
- Evaluate the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial HypercholesterolemiaStatus unknownPhase 2/3Shenzhen People's HospitalNCT04948008Written as IBI306
- Single Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Healthy Subjects.CompletedPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT03366688Written as IBI306
Given beside what is tested · 1 — tafolecimab is usual care or a partner of the new treatment
What changed recently
From the registry's own updates since Oct 17, 2026.
Started recruiting1
Codes
What other systems call tafolecimab · ClinicalTrials.gg INT017102
- UNII (FDA) KV2ZKH0NIMTAFOLECIMABOne source FDA
- NCI Thesaurus C171839TafolecimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | KV2ZKH0NIM | TAFOLECIMAB | One source FDA |
| NCI Thesaurus | C171839 | Tafolecimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.